መነሻ › አቴሮስክሌሮሲስ › South Carolina
በSouth Carolina ለአቴሮስክሌሮሲስ የሚደረጉ ክሊኒካዊ ጥናቶች
ለአቴሮስክሌሮሲስ የሚደረጉ 6 ጥናቶች በSouth Carolina ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በSouth Carolina ውስጥ ያሉ ከተሞች
Official study text (English)
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Monroe Biomedical Research - Charleston, North Charleston
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT07783802Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- M3 Wake Research - Charleston, Charleston
- Medical University of South Carolina, Charleston
- Walker Family Care, Little River
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2026 · NCT07157774Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Accellacare Charleston, Mt. Pleasant
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ45 እስከ 99 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07037433Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Columbia Nephrology, Columbia
- CN Clinical Research LLC, Greenville
- Dialysis Clinic, Inc., Spartanburg
- እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT05485961A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Charleston
- Research Site, Fort Mill
- Research Site, Mauldin
- እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ኦገስ 2026 · NCT07000357Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston
- Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC, Columbia
ተሳታዮችን በመፈለግ ላይደረጃ 4
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ዲሴም 2025 · NCT02915198ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።